Sean Gallup The U.S. FDA has lifted a partial clinical hold on a phase 1 trial of an antibody drug conjugate candidate under development by BioNTech ( NASDAQ: BNTX ) and MediLink Therapeutics (Suzhou).
The hold was placed in June over concerns about drug safety at higher doses. A decline in neutrophil count (neutropenia) and an increasing rate of mucositis events were observed. MediLink, which is the study sponsor, has lowered dose levels for participants that enrolled at higher dose levels.
The candidate, BNT326/YL202, is under investigation for solid tumors. More on BioNTech BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise Pfizer, BioNTech post partial win in late-stage trial for COVID/flu combo shot FDA is said to clear updated COVID shots as early as next week BioNTech SE (BNTX) Q2 2024 Earnings Call Transcript BioNTech SE 2024 Q2 - Results - Earnings Call Presentation.
